{"id":"W4403213466","doi":"10.1016/j.euo.2024.09.013","title":"Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Abiraterone; Prostate cancer; Abiraterone acetate; Olaparib; Asymptomatic; Placebo; Internal medicine; Oncology; Urology; Cancer; Androgen deprivation therapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000632962,0.0003695062,0.0009778821,0.0001961559,0.0001434247,0.00004275414,0.0001762201,0.00007120162,0.00004675611],"category_scores_gemma":[0.0001020285,0.0001763619,0.0000691019,0.0003748109,0.0008303196,0.00009517992,0.00006864672,0.0002282495,0.000007046338],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003394551,"about_ca_system_score_gemma":0.0005815984,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000351538,"about_ca_topic_score_gemma":0.0006798616,"domain_scores_codex":[0.9966766,0.001170685,0.0009110387,0.0005010719,0.0003436012,0.000397049],"domain_scores_gemma":[0.9971415,0.001903078,0.0003259569,0.0004162457,0.0001085134,0.0001046415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8848756,0.006244117,0.00796964,0.001307178,0.006735234,0.001420511,0.04160585,0.001051967,0.002057166,0.000100985,0.0002805016,0.04635125],"study_design_scores_gemma":[0.7284094,0.09770995,0.155013,0.000657414,0.006078746,0.00006233542,0.001276371,0.008149227,0.0005210029,0.00005542931,0.001643678,0.000423447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986634,0.005504786,0.00002707871,0.002416724,0.0001782999,0.004731949,0.0002608054,0.00003618463,0.0002102318],"genre_scores_gemma":[0.9978355,0.001143115,0.0001634837,0.0001148418,0.00008170534,0.000310439,0.0002344524,0.00004653665,0.00006990383],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1564662,"threshold_uncertainty_score":0.7191829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06115839959823703,"score_gpt":0.3709653573860134,"score_spread":0.3098069577877763,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}